JP5560268B2 - 胃保持型医薬剤形 - Google Patents

胃保持型医薬剤形 Download PDF

Info

Publication number
JP5560268B2
JP5560268B2 JP2011514137A JP2011514137A JP5560268B2 JP 5560268 B2 JP5560268 B2 JP 5560268B2 JP 2011514137 A JP2011514137 A JP 2011514137A JP 2011514137 A JP2011514137 A JP 2011514137A JP 5560268 B2 JP5560268 B2 JP 5560268B2
Authority
JP
Japan
Prior art keywords
polymer
dosage form
pharmaceutical dosage
unit
gastric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011514137A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012504551A (ja
JP2012504551A5 (OSRAM
Inventor
ビネス・ピレイ
ヤヒャ・チョーナラ
カラー・マーフィー
サラシュニー・モーニサミ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of the Witwatersrand, Johannesburg
Original Assignee
University of the Witwatersrand, Johannesburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of the Witwatersrand, Johannesburg filed Critical University of the Witwatersrand, Johannesburg
Publication of JP2012504551A publication Critical patent/JP2012504551A/ja
Publication of JP2012504551A5 publication Critical patent/JP2012504551A5/ja
Application granted granted Critical
Publication of JP5560268B2 publication Critical patent/JP5560268B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2011514137A 2008-06-19 2009-06-03 胃保持型医薬剤形 Expired - Fee Related JP5560268B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ZA200710997 2008-06-19
ZA2007/10997 2008-06-19
PCT/IB2009/005828 WO2009153632A1 (en) 2008-06-19 2009-06-03 A gastroretentive pharmaceutical dosage form

Publications (3)

Publication Number Publication Date
JP2012504551A JP2012504551A (ja) 2012-02-23
JP2012504551A5 JP2012504551A5 (OSRAM) 2012-09-06
JP5560268B2 true JP5560268B2 (ja) 2014-07-23

Family

ID=44309136

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011514137A Expired - Fee Related JP5560268B2 (ja) 2008-06-19 2009-06-03 胃保持型医薬剤形

Country Status (5)

Country Link
US (1) US8778396B2 (OSRAM)
EP (1) EP2306983A1 (OSRAM)
JP (1) JP5560268B2 (OSRAM)
WO (1) WO2009153632A1 (OSRAM)
ZA (1) ZA200903854B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102307574A (zh) * 2008-10-08 2012-01-04 鲍斯生命科学Pvt有限公司 缓释给药系统
WO2011053917A2 (en) * 2009-11-01 2011-05-05 Adeona Pharmaceuticals, Inc. Gastroretentive oral high dose zinc preparations
EP2444064A1 (en) * 2010-10-22 2012-04-25 Meliatys Process for making multiparticulate gastroretentive dosage forms
US8589775B2 (en) * 2011-03-14 2013-11-19 Infineon Technologies Ag Error tolerant flip-flops
CN104666267B (zh) * 2015-03-27 2017-08-08 康普药业股份有限公司 一种阿昔洛韦药物组合物
KR20180004756A (ko) 2015-05-06 2018-01-12 신애질 코포레이션 약물 입자를 함유하는 제약 현탁액, 그의 투여를 위한 장치, 및 그의 사용 방법
CN109310653A (zh) 2016-03-17 2019-02-05 硫创治疗公司 用于控制释放半胱胺和系统治疗半胱胺敏感性病症的组合物
ES3024932T3 (en) 2017-09-20 2025-06-05 Thiogenesis Therapeutics Inc Compounds for the treatment of cysteamine sensitive disorders
WO2019126214A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
AU2018388577B2 (en) * 2017-12-18 2024-06-06 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
CA3085941A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
US10835489B2 (en) 2018-03-09 2020-11-17 University Of Saskatchewan Modified release formulations of mycophenolate mofetil
KR20210031910A (ko) * 2018-06-19 2021-03-23 싱가포르국립대학교 다양한 적응증에 대한 향상된 생체 이용률을 위한 5-하이드록시트립토판의 제형
CN109925289B (zh) * 2019-04-11 2021-05-25 海南普利制药股份有限公司 地氯雷他定分散片
WO2020230089A1 (en) 2019-05-14 2020-11-19 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions
EP4362919A1 (en) 2021-07-30 2024-05-08 Evecxia Therapeutics, Inc. 5-hydroxytryptophan gastroretentive dosage forms
US12409163B2 (en) 2021-07-30 2025-09-09 Evecxia Therapeutics, Inc. Method of enhancing 5-hydroxytryptophan (5-HTP) exposure
JP2024535585A (ja) 2021-10-14 2024-09-30 エヴェクシア セラピューティクス， インク． 脳内５－ヒドロキシトリプタミンの機能を治療目的で最適化する方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0998271B3 (en) 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
NZ523747A (en) * 1998-09-14 2004-04-30 Ranbaxy Lab Ltd Pharmaceutical composition comprising a drug, a gas generating component, a swelling agent, a viscolyzing agent and a gel forning polymer
US6797283B1 (en) * 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
AU2002363998A1 (en) * 2001-12-15 2003-06-30 Spherics, Inc. Bioadhesive drug delivery system with enhanced gastric retention
JP2004002320A (ja) * 2002-03-04 2004-01-08 Medorekkusu:Kk 生体内で相転移する液状マトリックスおよび液状経口製剤
US20070196396A1 (en) 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
WO2005084639A2 (en) * 2004-03-03 2005-09-15 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
MX2008000099A (es) * 2005-06-29 2008-03-19 Panacea Biotec Ltd Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
WO2007106957A1 (en) 2006-03-21 2007-09-27 Laboratoires Smb S.A. Multiple units controlled-release floating dosage forms
US20080268045A1 (en) * 2006-11-09 2008-10-30 Proprius Pharmaceuticals, Inc. Sustained release methotrexate formulations and methods of use thereof

Also Published As

Publication number Publication date
ZA200903854B (en) 2011-02-23
JP2012504551A (ja) 2012-02-23
US8778396B2 (en) 2014-07-15
EP2306983A1 (en) 2011-04-13
US20110182988A1 (en) 2011-07-28
WO2009153632A1 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
JP5560268B2 (ja) 胃保持型医薬剤形
Streubel et al. Gastroretentive drug delivery systems
Chawla et al. A means to address regional variability in intestinal drug absorption
Stops et al. Floating dosage forms to prolong gastro-retention—The characterisation of calcium alginate beads
JP5580815B2 (ja) 経粘膜デリバリーシステム
Shah et al. Gastroretentive drug delivery systems: from conception to commercial success
BRPI0015061B1 (pt) comprimido revestido tendo alta dosagem de cloridrato de sevelamer
JP2013519726A (ja) バクロフェン療法に感受性の病状の治療方法
Gunda et al. Formulation development and evaluation of gastro retentive drug delivery systems-a review
Auriemma et al. Polysaccharides based gastroretentive system to sustain piroxicam release: Development and in vivo prolonged anti-inflammatory effect
Tadros et al. Controlled-release triple anti-inflammatory therapy based on novel gastroretentive sponges: characterization and magnetic resonance imaging in healthy volunteers
CN111741748B (zh) 一种普瑞巴林缓释组合物及其制备方法
CN111053749B (zh) 一种普瑞巴林缓释组合物及其制备方法
Chen et al. Development and characterization of a gastroretentive dosage form composed of chitosan and hydroxyethyl cellulose for alendronate
Teaima et al. Comprehensive overview on recent updates of gastroretentive raft-forming systems
Hsein et al. Denatured whey protein powder as a new matrix excipient: design and evaluation of mucoadhesive tablets for sustained drug release applications
Varshi et al. A review on Advanced approaches and polymers used in gastroretentive drug delivery systems.
AU2014368504B2 (en) Gastro-retentive oral pharmaceutical compositions
Pawar et al. Superporous Hydrogel: A Novel Approach for Safe Gastroretentive Drug Delivery System.
Ahmed et al. A conceptual overview on superporous hydrogels
Bhatta et al. Swelling and mucoadhesive behavior with drug release characteristics of gastoretentive drug delivery system based on a combination of natural gum and semi-synthetic polymers
Jacob et al. ORAL IN-SITU GELLING SYSTEM–A REVIEW
Chavda et al. A newer formulation approach: Superporous hydrogel composite-based bioadhesive drug-delivery system
Mali et al. A review on gastroretentive floating drug delivery system
JP6532529B2 (ja) ミソプロストール分散性錠剤

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131008

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20131011

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20131219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140107

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140407

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140513

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140609

R150 Certificate of patent or registration of utility model

Ref document number: 5560268

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees